CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07382739
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:55.520912+00:00
Published At: 2026-04-14T00:00:00+00:00
Record Updated At: 2026-04-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Phase 2", "Radiotherapy-Induced Immune Priming", "Elranatamab", "Relapsed Refractory Multiple Myeloma (RRMM)", "Extramedullary Disease in Multiple Myeloma", "Paramedullary Disease", "PMD"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-14"
protocolSection.identificationModule.nctId: "NCT07382739"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) \"PRIME-EMD-PMD\""
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.